Chargement en cours...
Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial
BACKGROUND: FOLFIRI plus bevacizumab have been widely used as first-line treatment for metastatic colorectal cancer (mCRC). Pharmacokinetics and pharmacodynamics suggested a low dose of irinotecan given as a long-term infusion is expected to enhance antitumor activity. We conducted a randomized phas...
Enregistré dans:
| Publié dans: | Oncology |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
S. Karger AG
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7592907/ https://ncbi.nlm.nih.gov/pubmed/32474564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000507293 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|